Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity.
Research paper by
Danish D Saleheen, Pradeep P Natarajan, Irina M IM Armean, Wei W Zhao, Asif A Rasheed, Sumeet A SA Khetarpal, Hong-Hee HH Won, Konrad J KJ Karczewski, Anne H AH O'Donnell-Luria, Kaitlin E KE Samocha, Benjamin B Weisburd, Namrata N Gupta, Mozzam M Zaidi, Maria M Samuel, Atif A Imran, Shahid S Abbas, Faisal F Majeed, Madiha M Ishaq, Saba S Akhtar, Kevin K Trindade, Megan M Mucksavage, Nadeem N Qamar, Khan Shah KS Zaman, Zia Z Yaqoob, Tahir T Saghir, Syed Nadeem Hasan SN Rizvi, Anis A Memon, Nadeem N Hayyat Mallick, Mohammad M Ishaq, Syed Zahed SZ Rasheed, Fazal-Ur-Rehman FU Memon, Khalid K Mahmood, Naveeduddin N Ahmed, Ron R Do, Ronald M RM Krauss, Daniel G DG MacArthur, Stacey S Gabriel, Eric S ES Lander, Mark J MJ Daly, Philippe P Frossard, John J Danesh, Daniel J DJ Rader, Sekar S Kathiresan
A major goal of biomedicine is to understand the function of every gene in the human genome. Loss-of-function mutations can disrupt both copies of a given gene in humans and phenotypic analysis of such 'human knockouts' can provide insight into gene function. Consanguineous unions are more likely to result in offspring carrying homozygous loss-of-function mutations. In Pakistan, consanguinity rates are notably high. Here we sequence the protein-coding regions of 10,503 adult participants in the Pakistan Risk of Myocardial Infarction Study (PROMIS), designed to understand the determinants of cardiometabolic diseases in individuals from South Asia. We identified individuals carrying homozygous predicted loss-of-function (pLoF) mutations, and performed phenotypic analysis involving more than 200 biochemical and disease traits. We enumerated 49,138 rare (<1% minor allele frequency) pLoF mutations. These pLoF mutations are estimated to knock out 1,317 genes, each in at least one participant. Homozygosity for pLoF mutations at PLA2G7 was associated with absent enzymatic activity of soluble lipoprotein-associated phospholipase A2; at CYP2F1, with higher plasma interleukin-8 concentrations; at TREH, with lower concentrations of apoB-containing lipoprotein subfractions; at either A3GALT2 or NRG4, with markedly reduced plasma insulin C-peptide concentrations; and at SLC9A3R1, with mediators of calcium and phosphate signalling. Heterozygous deficiency of APOC3 has been shown to protect against coronary heart disease; we identified APOC3 homozygous pLoF carriers in our cohort. We recruited these human knockouts and challenged them with an oral fat load. Compared with family members lacking the mutation, individuals with APOC3 knocked out displayed marked blunting of the usual post-prandial rise in plasma triglycerides. Overall, these observations provide a roadmap for a 'human knockout project', a systematic effort to understand the phenotypic consequences of complete disruption of genes in humans.